Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene cream for acne-induced post-inflammatory hyperpigmentation
2021-003608-41Phase 4Completed
- Sponsor
- Galderma
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acne vulgaris and Post-inflammatory hyperpigmentation (PIH) comparing Trifarotene 50 µg/g cream with Vehicle cream (2 arms). Primary endpoint: Change in PIH Overall Disease Severity at Week 24. Started Nov 2021; status: completed.
02
Drugs
trifarotene
03
Conditions
acne vulgarisPost-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on 2021-003608-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003608-41.